Appointments: Rice Goes To CVS, A New CFO At J&J And Changes at Merck & Co, Alder, Hansa, OncoMed, Modus Therapeutics, Astellas Americas And Others
This week's new appointments include the move by the second former big pharma executive to a PBM in the space of a week, plus a new CFO at Johnson & Johnson, and new CEOs at Alder BioPharmaceuticals, OncoMed and Hansa Medical. Other hires were announced by Astellas Americas, Merck & Co, Valbiotis, Bicycle Therapeutics, Sorrento Therapeutics, Gritstone Oncology and Oxford BioMedica.
You may also be interested in...
Former GSK CEO Witty stood out among big pharma chief execs for his pessimistic outlook on US drug pricing, which shaped his diversification strategy at GSK. His experience as a pharma insider makes him an interesting choice to lead United's PBM and health services arm.
The UK backs the world's first COVID-19 human challenge studies to accelerate research – though the first results will not be ready until mid-2021.
New chief business officer named at Ovoca Bio, and a new chairman at Opthea Ltd.